MX2022003065A - Conjugados de proteína-macromolécula y métodos de uso de estos. - Google Patents

Conjugados de proteína-macromolécula y métodos de uso de estos.

Info

Publication number
MX2022003065A
MX2022003065A MX2022003065A MX2022003065A MX2022003065A MX 2022003065 A MX2022003065 A MX 2022003065A MX 2022003065 A MX2022003065 A MX 2022003065A MX 2022003065 A MX2022003065 A MX 2022003065A MX 2022003065 A MX2022003065 A MX 2022003065A
Authority
MX
Mexico
Prior art keywords
conjugates
protein
methods
macromolecule
macromolecule conjugates
Prior art date
Application number
MX2022003065A
Other languages
English (en)
Inventor
Hui Li
Haiping Zhou
Yuntao Song
Chuan Liao
Original Assignee
Beijing Xuanyi Pharmasciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Xuanyi Pharmasciences Co Ltd filed Critical Beijing Xuanyi Pharmasciences Co Ltd
Publication of MX2022003065A publication Critical patent/MX2022003065A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona conjugados de proteína-macromolécula, enlazadores liberables y macromoléculas, tal como se define en la presente. Los conjugados descritos proporcionan propiedades únicas que se basan al menos en las propiedades del enlazador y la cantidad de restos enlazador-macromolécula. También se proporciona en la presente un método de síntesis y uso de conjugados en el tratamiento de enfermedades y trastornos.
MX2022003065A 2019-09-30 2020-09-30 Conjugados de proteína-macromolécula y métodos de uso de estos. MX2022003065A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962908435P 2019-09-30 2019-09-30
PCT/US2020/053572 WO2021067458A1 (en) 2019-09-30 2020-09-30 Protein-macromolecule conjugates and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022003065A true MX2022003065A (es) 2022-06-09

Family

ID=75337536

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003065A MX2022003065A (es) 2019-09-30 2020-09-30 Conjugados de proteína-macromolécula y métodos de uso de estos.

Country Status (12)

Country Link
US (1) US20220401561A1 (es)
EP (1) EP4037715A4 (es)
JP (1) JP2022549295A (es)
KR (1) KR20220074897A (es)
CN (1) CN114630818A (es)
AU (1) AU2020360397A1 (es)
BR (1) BR112022005465A2 (es)
CA (1) CA3153644A1 (es)
IL (1) IL291730A (es)
MX (1) MX2022003065A (es)
TW (1) TW202126332A (es)
WO (1) WO2021067458A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022103983A2 (en) * 2020-11-11 2022-05-19 Sutro Biopharma, Inc. Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
CN113929731B (zh) * 2021-12-16 2022-05-10 北京春雷杰创生物科技有限公司 一种促进低分子量蛋白体外复性和提高免疫原性的方法
WO2023244517A1 (en) * 2022-06-16 2023-12-21 Merck Sharp & Dohme Llc Interleukin-2 prodrugs
CN115947745B (zh) * 2022-12-26 2024-02-27 中山大学 一种基于白蛋白的光热转换纳米材料及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240773A1 (en) * 2009-03-23 2010-09-23 Kenneth Korzekwa Multifunctional linkers
WO2011140376A1 (en) * 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from dendrimers
ES2584381T3 (es) * 2010-05-05 2016-09-27 Prolynx Llc Liberación controlada de compuestos activos desde conjugados macromoleculares
EP2566334B1 (en) * 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
KR102109067B1 (ko) * 2011-09-07 2020-05-13 프로린크스 엘엘시 생분해성 교차결합을 가지는 하이드로젤
WO2013036857A1 (en) * 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
EP2768856A4 (en) * 2011-10-18 2015-05-27 Prolynx Llc PEG CONJUGATES OF EXENATIDE
KR20160075665A (ko) * 2013-10-22 2016-06-29 프로린크스 엘엘시 소마토스타틴 및 그 유사체의 컨쥬게이트
EP3598983A1 (en) * 2014-10-03 2020-01-29 Synaffix B.V. Sulfamide linker, conjugates thereof, and methods of preparation

Also Published As

Publication number Publication date
EP4037715A4 (en) 2023-12-13
BR112022005465A2 (pt) 2022-06-14
AU2020360397A1 (en) 2022-03-31
TW202126332A (zh) 2021-07-16
CA3153644A1 (en) 2021-04-08
US20220401561A1 (en) 2022-12-22
KR20220074897A (ko) 2022-06-03
JP2022549295A (ja) 2022-11-24
IL291730A (en) 2022-05-01
CN114630818A (zh) 2022-06-14
WO2021067458A1 (en) 2021-04-08
EP4037715A1 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
MX2022003065A (es) Conjugados de proteína-macromolécula y métodos de uso de estos.
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
NZ754051A (en) Novel antibodies and uses thereof
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
PH12018501777A1 (en) Derivatives of amanita toxins and their conjugation to a cell binding molecule
NZ725480A (en) Anti-ptk7 antibody-drug conjugates
WO2018236870A3 (en) METHODS AND COMPOSITIONS FOR TARGETING CANCER CELLS WITH A CHIMERIC ANTIGENIC RECEPTOR
NZ741261A (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
WO2015151080A3 (en) Specific conjugation of cell-binding molecules
MX2020012997A (es) Conjugados de anticuerpo modulador de empalme-farmaco y metodos de uso.
MX2021010550A (es) Conjugados de anticuerpo-farmaco hidrofilicos.
NZ737471A (en) Hydrophilic linkers for conjugation
MY148860A (en) Fused amino pyridine as hsp90 inhibitors
MX2010000465A (es) Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
MX2010005022A (es) Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
MX2015011583A (es) Derivados de amatoxina.
JOP20210253A1 (ar) أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ psma
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
MX2021015533A (es) Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
JOP20190191A1 (ar) وحدات شجرية علاجية
ZA202203201B (en) Therapeutic conjugates
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2021003186A (es) Nuevos conjugados de hidrogel.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.